N/A
Manufactured by ANI Pharmaceuticals, Inc.
27,404 FDA adverse event reports analyzed
Last updated: 2026-04-14
BICALUTAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for BICALUTAMIDE include FATIGUE, DEATH, PROSTATIC SPECIFIC ANTIGEN INCREASED, ASTHENIA, HOT FLUSH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BICALUTAMIDE.
Out of 14,924 classified reports for BICALUTAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 27,404 FDA FAERS reports that mention BICALUTAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, DEATH, PROSTATIC SPECIFIC ANTIGEN INCREASED, ASTHENIA, HOT FLUSH, PROSTATE CANCER. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with BICALUTAMIDE. Always verify the specific product and NDC with your pharmacist.